



**Nanobody S+16a protects the phenotype and viability of Treg from the effects of NAD<sup>+</sup>.**

A C57BL/6 mouse was injected (i.v.) with 50 µg of Treg-Protector™, 15 minutes before harvesting the spleen to isolate the lymphocytes. Control mouse only received PBS. The cells were incubated 1h at 37°C, and then stained with CD3 Brilliant Violet 605™, CD4 FITC, CD25 PE/Dazzle™ 594, and Annexin V Brilliant Violet 421™. Data shown was gated on FSC vs SSC splenocytes, and CD3<sup>+</sup> and CD4<sup>+</sup> population.

The cells from the control mouse showed a high susceptibility to NICD and shedding of CD27 and CD62L. In contrast, the cells from the mouse treated with S+16a retained their phenotype.